2017-02-22 16:16:54 UTC

What’s New at the 2017 AGA Postgraduate Course?

March 2, 2017

This year's course directors are introducing new initiatives, May 6 and 7, in Chicago.

It’s well-known that the AGA Postgraduate Course is a rapid way for you to catch up on the latest treatment advances in just 1.5 days. But the 2017 course directors are shaking some things up during the next course, May 6 and 7 in Chicago, IL. 

Measure
Test your knowledge — and how you stack up against fellow attendees — by participating in real-time pre- and post-tests given by each presenter through an Audience Response System. The presenter will address the question and answer it during the course of his/her talk.

Learn
Look to the future of GI during a new Hot Topics general session led by Uma Mahadevan, MD, AGAF, and Suzanne Rose, MD, MSEd, AGAF. After the President’s Welcome, topics will cover the latest in abdominal pain and opioid therapy, microbiome, viral hepatitis and FMT.

Apply
Every speaker has been tasked with presenting at least one technological or therapeutic advance in their topic of discussion. This focuses on the future of GI and what attendees should be aware of.

Dr. Mahadevan outlines some things in the video below that you won't want to miss. Watch and then register today. Early bird registration pricing is available until March 22.

More on CME Credit

Advancing Collaborative Approaches in IBD Treatment Decision-Making

March 14, 2018

This is a unique opportunity for payers and providers to gather in the same room to discuss IBD therapy selection, disease monitoring, treatment criteria and access.

Advancing Collaborative Approaches in IBD Treatment Decision-Making

March 12, 2018

This is a unique opportunity for payers and providers to gather in the same room to discuss IBD therapy selection, disease monitoring, treatment criteria and access.

Advancing Collaborative Approaches in IBD Treatment Decision-Making

Jan. 9, 2018

This is a unique opportunity for payers and providers to gather in the same room to discuss IBD therapy selection, disease monitoring, treatment criteria and access.